Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

METBEIGE biomarker study

ABSTRACT: Interventions: investigational material(s) Generic name etc : Cabozantinib Malate INN of investigational material : Cabozantinib Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : Cabozantinib (administered in the main study): 40 mg or 60 mg, once daily at bedtime, oral, in a 28 day-course. control material(s) Generic name etc : - INN of investigational material : - Therapeutic category code : --- Other Dosage and Administration for Investigational material : - Primary outcome(s): pharmacogenomics Analyses will be performed of the following parameters using formalin-fixed and paraffin-embedded (FFPE) specimens and freshly frozen specimens prepared from tumor tissue collected for the METBEIGE study (before protocol treatment, before the start of the second cycle, and after discontinuation of protocol treatment) and blood specimens collected at the same time. The results obtained from the analyses will be integrated with clinical data obtained in the METBEIGE study to identify biomarkers of the effectiveness of the protocol treatment. 1)Analysis of cancer-related genetic abnormalities 2)Protein expression analysis 3)RNA expression analysis 4)Analysis of cancer cell lines and organoids 5)Patient-derived Xenografts (PDX) analysis Study Design: exploratory research

DISEASE(S): Colorectal Cancer

PROVIDER: 98266 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

METBEIGE Study

Project description:Interventions: investigational material(s) Generic name etc : Cabozantinib Malate INN of investigational material : Cabozantinib Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : Cabozantinib: 40 mg or 60 mg, once daily at bedtime, oral, in a 28 day-course. control material(s) Generic name etc : - INN of investigational material : - Therapeutic category code : Dosage and Administration for Investigational material : - Primary outcome(s): safety efficacy - Proportion of subjects with DLT (phase 1 part) - Confirmed ORR by investigators’ assessment in patients who received study treatment as 3rd line or later (phase 2 part) Study Design: An open-label, single arm phase I study and an open-label, randomized controlled multicenter phase II study

| 102460 | ecrin-mdr-crc

DS-Screen

Project description:Interventions: investigational material(s) Generic name etc : - INN of investigational material : - Therapeutic category code : --- Other Dosage and Administration for Investigational material : - control material(s) Generic name etc : - INN of investigational material : - Therapeutic category code : Dosage and Administration for Investigational material : - Primary outcome(s): exploratory FGFR2 and HER2 protein expression IHC Study Design: Observational study

| 98039 | ecrin-mdr-crc

A Randomized Phase III Trial of SOX/Bevacizumab versus FOLFOX/Bevacizmab in Treating Patients with Metastatic Colorectal Cancer (SOFT).

Project description:Interventions: investigational material(s) Generic name etc : S-1 (tegafur + gimeracil + oteracil potassium) INN of investigational material : S-1: tegafur, gimeracil, oteracil potassium Therapeutic category code : 422 Antimetabolic agents Dosage and Administration for Investigational material : 40-60 mg bid day 1 (evening) - day 15 (morning). Repeat cycles every 3 weeks Generic name etc : L-OHP (Oxaliplatin) INN of investigational material : oxaliplatin Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : 130 mg/m2 IV on day 1. Repeat cycles every 3 weeks Generic name etc : BV (Bevacizumab) INN of investigational material : bevacizumab Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : 7.5 mg/kg IV on day 1. Repeat cycles every 3 weeks control material(s) Generic name etc : 5-FU (Fluorouracil) INN of investigational material : fluorouracil Therapeutic category code : 422 Antimetabolic agents Dosage and Administration for Investigational material : 400 mg/m2 IV bolus on day 1, followed by 2400 mg/m2 over 46 hours. Repeat cycles every 2 weeks. Generic name etc : l-LV (Levofolinate calcium) INN of investigational material : folic acid Therapeutic category code : 392 Antidotes Dosage and Administration for Investigational material : 200 mg IV on day 1. Repeat cycles every 2 weeks. Generic name etc : L-OHP (Oxaliplatin) INN of investigational material : oxaliplatin Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : 85 mg/m2 IV on day 1. Repeat cycles every 2 weeks. Generic name etc : BV (Bevacizumab) INN of investigational material : bevacizumab Therapeutic category code : 429 Other antitumor agents Dosage Primary outcome(s): Progression free survival(PFS) Study Design: Randomized, open-label, comparative study

| 97778 | ecrin-mdr-crc

A prospective observational study of the efficacy and safety of CPT-11 based regimens for UGT1A1 genotype guided patients with metastatic colorectal cancer

Project description:Interventions: investigational material(s) Generic name etc : Irinotecan hydrochloride INN of investigational material : Therapeutic category code : 424 Antineoplastic preparations extracted from plants Dosage and Administration for Investigational material : Approved doses and schedules control material(s) Generic name etc : None INN of investigational material : Therapeutic category code : --- Other Dosage and Administration for Investigational material : None Primary outcome(s): Progression free survival None Study Design: Prospective, cohort

| 97784 | ecrin-mdr-crc

Phase 2 study of DS-8201a in subjects with colorectal cancer [DESTINY-CRC01]

Project description:Interventions: investigational material(s) Generic name etc : DS-8201a INN of investigational material : trastuzumab deruxtecan Therapeutic category code : 42- Antineoplastic agents Dosage and Administration for Investigational material : IV solution (Once every 3 weeks, 6.4 mg/kg) control material(s) Generic name etc : - INN of investigational material : - Therapeutic category code : Dosage and Administration for Investigational material : - Primary outcome(s): efficacy The objective response rate RECIST Version 1.1 Study Design: multi center, open-label, 3-cohort study

| 102108 | ecrin-mdr-crc

A Phase 1 Study of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer

Project description:Interventions: investigational material(s) Generic name etc : OCV-C02 INN of investigational material : - Therapeutic category code : 42- Antineoplastic agents Dosage and Administration for Investigational material : Once-weekly subcutaneous injection (0.3, 1 3 and 6 mg/body) control material(s) Generic name etc : - INN of investigational material : - Therapeutic category code : Dosage and Administration for Investigational material : - Primary outcome(s): safety Dose Limiting Toxicity (DLT) Common Terminology Criteria for Adverse Events (CTCAE), ver. 4.0 Study Design: multicenter, open, non-comparative study

| 100907 | ecrin-mdr-crc

ONO-4538/CA2099X8 Phase 2/3 Study(ONO-4538-72/CA2099X8)

Project description:Interventions: investigational material(s) Generic name etc : ONO-4538/BMS-936558 INN of investigational material : Nivolumab Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : Intravenous administration control material(s) Generic name etc : Fluorouracil, Leucovorin Calcium Folinate, Oxaliplatin, Bevacizumab INN of investigational material : Fluorouracil, Leucovorin Calcium Folinate, Oxaliplatin, Bevacizumab Therapeutic category code : 42- Antineoplastic agents Dosage and Administration for Investigational material : Intravenous administration Primary outcome(s): efficacy PFS Study Design: Randomized, open-label

| 102159 | ecrin-mdr-crc

NK012 phase II clinical study

Project description:Interventions: investigational material(s) Generic name etc : NK012(other antitumor agents) INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : Intravenous

| 98783 | ecrin-mdr-crc

Safety comformation study of R435 (Bevacizumab) in patients with metastatic colorectal cancer

Project description:Interventions: investigational material(s) Generic name etc : Bevacizumab INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : Injection Primary outcome(s): Safety Study Design: Open, Single Arm study

| 99347 | ecrin-mdr-crc

Phase II Study of S-1 plus LV (1 week on and 1 week off) as First-line Treatment for Patients with metastatic colorectal cancer.

| 99793 | ecrin-mdr-crc